分子肿瘤诊断市场 - 2018-2028年全球行业规模、份额、趋势、竞争、机会和预测，按产品类型、技术、应用、癌症类型、终端用户和地区细分

预计在 2024-2028 年的预测期内，全球分子肿瘤诊断市场将保持稳定的复合年增长率。这可归因于癌症、心血管疾病和糖尿病等各种慢性疾病的发病率不断上升。根据全球癌症观察站（Global Cancer Observatory）的数据，2020 年全球新增癌症病例约为 19,292,789 例，其中男性病例为 10,065,305 例，女性病例为 9,227,484 例。癌症是由于癌细胞不受控制地从内层向外层扩散而引起的。分子肿瘤学诊断是指诊断癌症的检测。这些检测用于识别遗传物质、蛋白质或相关化学物质，并提供有关健康或疾病的信息。然而，目前需要开发新的诊断方法和仪器，预计这将进一步推动分子肿瘤诊断市场的增长。

癌症发病率上升

癌症是世界上最常见的死亡原因之一。全球癌症病例的增加可能是肿瘤分子诊断市场增长的一个因素。根据美国癌症协会的数据，2021 年美国新增癌症病例 180 万例，癌症死亡病例 60 万例。由于癌细胞的扩散，医学专家正在加大研发力度，开发有助于预防和治疗癌症的治疗和诊断服务。据美国癌症协会称，肺癌、前列腺癌、肠癌和女性乳腺癌是全球四大癌症类型，占所有新发癌症病例的 43%。例如，美国癌症协会估计，到 2022 年，美国将新增 106 180 例结肠癌和 44 850 例直肠癌。此外，根据美国癌症协会的 2020 年报告，包括美国国家综合癌症网络（NCCN）、美国临床肿瘤学会（ASCO）和美国病理学家学会（CAP）在内的一些专业协会已经制定了生物标记物检测和治疗指南。因此，它们的治疗或诊断成像技术将推动全球分子肿瘤诊断市场的增长。

技术进步

先进技术包括基因组学测序技术。例如，癌症基因组测序技术、计算分析、肿瘤模型以及现代癌症研究机构正在进行的创新和研究的进步促进了癌症及其突变的早期检测。例如，2020 年 6 月，美国食品和药物管理局（FDA）批准了 Cobas 表皮生长因子受体基因突变检测试剂盒，这是一种用于检测非小细胞肺癌患者的基因突变检测试剂盒，它是一种实时检测试剂盒，可以识别表皮生长因子受体基因中的抗癌突变和 42 种突变。该分子检验由美国罗氏分子系统公司开发。

近期发展与产品上市

研究与开发（R&D）实践和活动的快速发展推动了市场的增长，因为人们越来越需要开发新型诊断解决方案来治疗癌症等危及生命的疾病。例如，2022年8月，Guardant Health公司扩大了其Guardant Reveal测试的使用范围，开发出一种液体活检测试，用于残留疾病检测和复发监测，包括早期乳腺癌和肺癌。目前，乳腺癌和肺癌患者可以使用这种检测方法，它也是唯一一种针对结直肠癌（CRC）的无组织检测方法。

此外，2021 年 12 月，QIAGEN 与 Denovo Biopharma 合作开发了用于治疗弥漫大 B 细胞淋巴瘤的辅助诊断检测。该检验能确定哪些人具有 Denovo 基因组标记 1 (DGM1)，对 Denovo 抗癌药物 DB102 有反应。

可用定制：

有了给定的市场数据，TechSci Research 可以根据公司的具体需求提供定制服务。报告可提供以下定制选项：

公司信息

• 其他市场参与者（最多五家）的详细分析和概况。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 覆盖市场
  • 研究年份
  • 主要市场细分

第 2 章：研究方法

• 研究目的
• 基准方法
• 主要行业合作伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概述
• 主要市场细分概述
• 主要市场参与者概述
• 主要地区/国家概述
• 市场驱动因素、挑战和趋势概述

第4章：客户之声

第5章：全球分子肿瘤诊断市场前景

• 市场规模与预测
  • 按价值
• 市场份额与预测
  • 按产品类型（仪器、试剂盒和化验、软件）
  • 按技术（荧光原位杂交（FISH）、新一代测序（NGS）、聚合酶链反应（PCR）、免疫组化（IHC）、流式细胞术及其他技术）
  • 按应用（研究、临床）
  • 按癌症类型（实体瘤（乳腺癌、卵巢癌、前列腺癌、肺癌、结直肠癌和其他实体瘤）、血癌（淋巴瘤、白血病、多发性骨髓瘤和其他血液恶性肿瘤）}分类
  • 按最终用户（医院和诊断中心、参考实验室、制药和生物技术公司、学术和研究机构）
  • 按地区（北美、欧洲、亚太地区、南美、中东和非洲）
  • 按公司（2022 年）
• 市场地图
  • 按产品类型
  • 按技术
  • 按应用
  • 按癌症类型
  • 按最终用户
  • 按地区

第6章：北美分子肿瘤诊断市场前景

• 市场规模与预测
  • 按价值
• 市场份额与预测
  • 按产品类型
  • 按技术
  • 按应用
  • 按癌症类型
  • 按最终用户
  • 按国家
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲分子肿瘤诊断市场前景

• 市场规模与预测
  • 按价值
• 市场份额与预测
  • 按产品类型
  • 按技术
  • 按应用
  • 按癌症类型
  • 按最终用户
  • 按国家
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 意大利
  • 西班牙

第 8 章 : 亚太地区分子肿瘤诊断市场前景

• 市场规模与预测
  • 按价值
• 市场份额与预测
  • 按产品类型
  • 按技术
  • 按应用
  • 按癌症类型
  • 按最终用户
  • 按国家
• 亚太地区：国家分析
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳大利亚

第 9 章 : 南美分子肿瘤诊断市场前景

• 市场规模与预测
  • 按价值
• 市场份额与预测
  • 按产品类型
  • 按技术
  • 按应用
  • 按癌症类型
  • 按最终用户
  • 按国家
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲分子肿瘤诊断市场前景

• 市场规模与预测
  • 按价值
• 市场份额与预测
  • 按产品类型
  • 按技术
  • 按应用
  • 按癌症类型
  • 按最终用户
  • 按国家
• 中东和非洲：国家分析
  • 阿联酋 分子肿瘤学诊断
  • 沙特阿拉伯 分子肿瘤学诊断产品
  • 南非 分子肿瘤学诊断

第 11 章 ：市场动态

• 驱动因素
• 挑战

第 12 章 ：市场趋势与发展

第 13 章 ：竞争格局

• 业务概述
• 产品供应
• 近期发展
• 财务状况（报告）
• 主要人员
  • Sysmex Corporation
  • F. Hoffmann-La Roche Ltd.
  • Myriad Genetics, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Danaher Corporation.
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • QIAGEN N.V.
  • Illumina, Inc.

第 14 章：战略建议

Global Molecular Oncology Diagnostics Market is anticipated to witness a steady CAGR in the forecast period, 2024-2028. This can be ascribed to the rising prevalence of various chronic diseases such as cancer, cardiovascular diseases, and diabetes, among others. According to Global Cancer Observatory, in 2020, around 19,292,789 new cancer cases were reported worldwide, among which the males and females accounted for 10,065,305 and 9 227,484 cases, respectively. Cancer is caused due to uncontrolled proliferation of cancer cells that starts from the inner lining to the outer region. Molecular oncology diagnostics refers to the tests for diagnosing cancer. These tests are used to identify the genetic material, proteins, or associated chemicals and provide information on health or disease. However, there is a need for developing new diagnostic methods and instruments, which is further expected to drive the growth of the Molecular Oncology Diagnostics Market.

The growing prevalence of cancer cases, the advanced technological advancement with the highest accuracy and precision, and the growing awareness amongst the population globally are projected to propel the growth of the market. Additionally, the high cost of molecular diagnostic techniques is expected to hamper the growth of the Global Molecular Oncology Diagnostics Market in the forecast years.

Rising Prevalence of Cancer

Cancer is one of the most common causes of death in the world. The global increase in cancer cases is probably a factor in the oncology molecular diagnostics market's growth. In the United States of America in 2021, there were 1.8 million new instances of cancer and 0.6 million cancer deaths, according to the American Cancer Society. Due to the proliferation of cancerous cells, medical professionals are increasing their research and development efforts to develop treatments and diagnostics services to aid the prevention and treatment of cancer. Lung, prostate, bowel, and female breast cancer make up the top four cancer types worldwide, accounting for 43% of all new cancer cases, according to the American Cancer Society. For instance, the American Cancer Society estimates that there will be 106,180 new instances of colon cancer and 44,850 new cases of rectal cancer in the United States by the year 2022. Additionally, several professional associations, including the National Comprehensive Cancer Network (NCCN), the American Association of Clinical Oncology (ASCO), and the College of American Pathologists (CAP), have developed biomarker testing and treatment guidelines, according to the American Cancer Society's 2020 report. Therefore, their treatment or diagnostic imaging is responsible for propelling the growth of Global Molecular Oncology Diagnostic Market.

Advancement in Technology

The advanced technology constitutes the sequencing techniques of genomics. For instance, the advancement in cancer genome sequencing technology, computational analysis, tumor models, and innovation and research going on in modern cancer research institutes promote early detection of cancer and its mutation. For instance, in June 2020, the United States Food and Drug Administration (FDA) gave approval to Cobas EGFR Mutation Test, a mutation test for testing patients with non-small cell lung cancer is a real-time test that can identify cancer resistance mutations and 42 mutations in the EGFR gene, which codes for the epidermal growth factor receptor. This molecular test was developed by a US-based company, namely Roche Molecular Systems, Inc.

Recent Developments & Product Launches

Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need for developing novel diagnostic solutions for the treatment of different life-threatening diseases like cancer. For instance, in August 2022, Guardant Health expanded its Guardant Reveal test usage and developed a liquid biopsy test for residual disease detection and recurrence monitoring, including early-stage breast and lung cancers. It is currently accessible to patients with breast and lung cancer and is the only tissue-free test for colorectal cancer (CRC).

Additionally, in December 2021, QIAGEN, in partnership with Denovo Biopharma, developed a companion diagnostic test for the treatment of diffuse large B-cell lymphoma. This test identified people who have the Denovo genomic marker 1 (DGM1), which responded to the Denovo cancer drug DB102.

Market Segmentation

Global Molecular Oncology Diagnostics Market can be segmented by product type, technology, application, cancer type, end user, region, and company. Based on product type, the market can be segmented into instruments, kits and assays, and software. Based on technology, the market is fragmented into fluorescence in-situ hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), flow cytometry, and other technologies. Based on application, the market is fragmented into Research and Clinical. Based on cancer type, the market is fragmented into solid tumors and blood cancers. Based on end users, the market is segmented into hospitals and diagnostic centers, reference laboratories, pharmaceutical and biotechnology companies, and academic and research institutes.

Advancement in Technology and Product Launch

The market players in Global Molecular Oncology Diagnostics Market are adopting various natural and modified strategies for market growth and development. For instance, a 5-year extension of their US supply agreement for the Insured ONE (FIT) fecal immunochemistry test was announced in January 2022 by Clinical Genomics, an innovator in the development of colorectal cancer testing, and Quest Diagnostics (NYSE: DGX), the world's largest provider of diagnostic information services. By delivering InSure FIT and the new InSure ONE FIT for colorectal cancer diagnostic programs, this arrangement improves an ongoing partnership. Amgen and Plexium established a multi-year partnership to find new targeted protein degradation treatments in February 2022. The multi-year partnership aids in the development of innovative molecular glue therapies by utilizing knowledge gained from Amgen's experience in creating multi-specific compounds. Furthermore, several strategies like collaboration, partnerships, mergers, acquisitions, product launches, and technology development propel the growth of Global Molecular Oncology Diagnostic Market.

Company Profiles

Sysmex Corporation, F. Hoffmann-La Roche Ltd., Myriad Genetics, Inc., HTG Molecular Diagnostics, Inc., Danaher Corporation, QIAGEN N.V., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., QIAGEN N.V., Illumina, Inc., etc. are some of the key players operating in the global molecular oncology diagnostics market.

Report Scope

In this report, Global Molecular Oncology Diagnostics Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Molecular Oncology Diagnostics Market, By Product Type:

• Instruments
• Kits and Assays
• Software

Molecular Oncology Diagnostics Market, By Technology:

• Fluorescence In-Situ Hybridization (FISH)
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Flow Cytometry
• Other Technologies

Molecular Oncology Diagnostics Market, By Application:

• Research
• Clinical

Molecular Oncology Diagnostics Market, By Cancer Type:

• Solid Tumor
  • Breast Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Other

• Blood Cancers
  • Lymphoma
  • Leukemia
  • Multiple Myeloma
  • Others

Molecular Oncology Diagnostics Market, By End User:

• Hospitals and Diagnostic Centers
• Reference Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes

Molecular Oncology Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Molecular Oncology Diagnostics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Molecular Oncology Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Instruments, Kits and Assays, Software)
  • 5.2.2. By Technology (Fluorescence In-Situ Hybridization (FISH), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Flow Cytometry, and Other Technologies)
  • 5.2.3. By Application (Research, Clinical)
  • 5.2.4. By Cancer Type {Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors), Blood cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)}
  • 5.2.5. By End User (Hospitals and Diagnostic Centers, Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes)
  • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East, and Africa)
  • 5.2.7. By Company (2022)
• 5.3. Market Map
  • 5.3.1. By Product Type
  • 5.3.2. By Technology
  • 5.3.3. By Application
  • 5.3.4. By Cancer Type
  • 5.3.5. By End User
  • 5.3.6. By Region

6. North America Molecular Oncology Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By Cancer Type
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Molecular Oncology Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Cancer Type
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Molecular Oncology Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Cancer Type
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Molecular Oncology Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Cancer Type
      • 6.3.3.2.5. By End User

7. Europe Molecular Oncology Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By Cancer Type
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Molecular Oncology Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Cancer Type
      • 7.3.1.2.5. By End User
  • 7.3.2. France Molecular Oncology Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Cancer Type
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Molecular Oncology Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Cancer Type
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Molecular Oncology Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Cancer Type
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Molecular Oncology Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Cancer Type
      • 7.3.5.2.5. By End User

8. Asia-Pacific Molecular Oncology Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By Cancer Type
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Molecular Oncology Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Cancer Type
      • 8.3.1.2.5. By End User
  • 8.3.2. Japan Molecular Oncology Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Cancer Type
      • 8.3.2.2.5. By End User
  • 8.3.3. India Molecular Oncology Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Cancer Type
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Molecular Oncology Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Cancer Type
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Molecular Oncology Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Cancer Type
      • 8.3.5.2.5. By End User

9. South America Molecular Oncology Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By Cancer Type
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Molecular Oncology Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Cancer Type
      • 9.3.1.2.5. By End User
  • 9.3.2. Argentina Molecular Oncology Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Cancer Type
      • 9.3.2.2.5. By End User
  • 9.3.3. Colombia Molecular Oncology Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Cancer Type
      • 9.3.3.2.5. By End User

10. Middle East and Africa Molecular Oncology Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By Cancer Type
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Molecular Oncology Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Cancer Type
      • 10.3.1.2.5. By End User
  • 10.3.2. Saudi Arabia Molecular Oncology Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Cancer Type
      • 10.3.2.2.5. By End User
  • 10.3.3. South Africa Molecular Oncology Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Cancer Type
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

• 13.1. Business Overview
• 13.2. Product Offerings
• 13.3. Recent Developments
• 13.4. Financials (As Reported)
• 13.5. Key Personnel
  • 13.5.1. Sysmex Corporation
  • 13.5.2. F. Hoffmann-La Roche Ltd.
  • 13.5.3. Myriad Genetics, Inc.
  • 13.5.4. HTG Molecular Diagnostics, Inc.
  • 13.5.5. Danaher Corporation.
  • 13.5.6. QIAGEN N.V.
  • 13.5.7. Bio-Rad Laboratories, Inc.
  • 13.5.8. Agilent Technologies, Inc.
  • 13.5.9. QIAGEN N.V.
  • 13.5.10. Illumina, Inc.

14. Strategic Recommendations